COMPANY

Nobilis Therapeutics Inc.

HQ: Portland, OR source · nobilistx.com ↗ · West Coast

Also known as Nobilis Therapeutics · 4 sources

Nobilis Therapeutics, Inc. is a Delaware C-corporation that is focused on therapeutic uses of inert gas mixtures and development of portable devices for their self-administration. From company website Source · Oct 13, 2026

Keywords: Post Traumatic Stress Disorder Parkinson Disease Panic Disorder NBTX-001 Xenon

Location: Portland, OR · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)1NIH grants

Timeline

2021-06 Trial start Phase 2/Phase 3: Xenon Inhalation for Treatment of Posttraumatic Stress Disorder source ↗
2021-06 Trial start Phase 2/Phase 3: Xenon Inhalation for Treatment of Panic Disorder source ↗
Dec 15, 2019 Trial start Phase 1: Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT03635827	Xenon Inhalation for Treatment of Posttraumatic Stress Disorder	Phase 2/Phase 3	Unknown status (ClinicalTrials.gov)	2021-06	2021-06 (estimated)
NCT04097080	Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease	Phase 1	Unknown status (ClinicalTrials.gov)	Dec 15, 2019	2021-11 (estimated)
NCT04432155	Xenon Inhalation for Treatment of Panic Disorder	Phase 2/Phase 3	Unknown status (ClinicalTrials.gov)	2021-06	2021-11 (estimated)

NIH awards 1

Annual award amounts. Total $320K.

Sep 17, 2021 NIH award 1R41DA055403-01 FY2021: $319,992 awarded for that fiscal year; activity R41 (STTR); PI BOGIN, VLAD; recipient as written: NOBILIS THERAPEUTICS, INC., PORTLAND, OR. Portable hand-held proprietary xenon inhal source ↗